De novo AML patients were organized into poor-, intermediate-, and good-prognosis risk groups according to karyotype definition
. | Cytogenetics prognosis group . | . | . | ||
|---|---|---|---|---|---|
| Capacity for engraftment . | Poor . | Intermediate . | Good . | ||
| Yes, no. patients | 5 | 18 | 0 | ||
| No, no. patients | 0 | 18 | 11 | ||
. | Cytogenetics prognosis group . | . | . | ||
|---|---|---|---|---|---|
| Capacity for engraftment . | Poor . | Intermediate . | Good . | ||
| Yes, no. patients | 5 | 18 | 0 | ||
| No, no. patients | 0 | 18 | 11 | ||
Four patients (nos. 7, 9, 10, 2) were excluded due to relapse, data were not collected for one patient (no. 22), and 2 karyotypes (nos. 4 and 5) failed at diagnosis. Engraftment correlates with poor prognosis; conversely, all favorable prognosis patients did not engraft.